Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome

Cubeddu, Alessandra; Bucci, Fiorella; Giannini, Andrea; Russo, Marinella; Daino, Diana; Russo, Natalia; Merlini, Sara; Pluchino, Nicola; Valentino, Valeria; Casarosa, Elena; Luisi, Stefano; Genazzani, Andrea Riccardo

doi:10.1016/j.psyneuen.2010.08.006

Cited by 79 publications

(35 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, all of our patients were using hormonal therapy and it is not clear whether it affects our results or not. However, there are some evidence that hormonal replacement therapy with estrogen and progesterone is positively correlated to BDNF in women (Begliuomini et al, 2007;Cubeddu et al, 2011). Third, the lack of female subjects is an important limitation of the study, and our findings are only informative about BDNF levels in male-tofemale individuals with GID compared to male controls.…”

Section: Discussionmentioning

confidence: 81%

Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder

Fontanari¹,

Andreazza²,

Costa³

et al. 2013

Journal of Psychiatric Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 81%

Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder

Fontanari¹,

Andreazza²,

Costa³

et al. 2013

Journal of Psychiatric Research

View full text Add to dashboard Cite

“…Although no differences were found in medication classes among the groups, antidepressants and neuroleptic medications may change inflammatory biomarkers,10,71 levels of BDNF,46 and oxidative stress parameters 49,66,72. Third, other potential variables associated with changes in biomarkers were not evaluated, including nutritional status73 and menstrual cycle 74. Fourth, although observational rating of PMD is necessary when using the CORE measure, observable PMD has been shown to be less distinctive in younger patients with seemingly true melancholic depression, while a valid rating of PMD requires observing patients at or near the nadir of their depressive episode 6.…”

Section: Discussionmentioning

confidence: 98%

Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure

Spanemberg¹,

Caldieraro²,

Vares³

et al. 2014

NDT

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to compare melancholic patients rated by the CORE measure of observable psychomotor disturbance with nonmelancholic and control subjects across a set of biomarkers.MethodsDepressed patients were classified as melancholic or nonmelancholic by using the CORE measure. Both groups of patients, as well as control subjects, were compared for a set of clinical and laboratory measures. Serum levels of brain-derived neurotrophic factor, of two markers of oxidative stress (protein carbonyl content [PCC] and thiobarbituric acid reactive substances [TBARS]), and of several immunity markers (interleukin [IL]-2, IL-4, IL-6, IL-10, IL-17, tumor necrosis factor-alpha, and interferon-gamma) were analyzed.ResultsThirty-three depressed patients and 54 healthy controls were studied. Depressive patients showed higher IL-4, IL-6, and PCC values than healthy controls. Thirteen (39%) of the depressed patients were assigned as melancholic by the CORE measure. They generated lower interferon-gamma (compared with nonmelancholic depressed patients) and TBARS (compared with both the nonmelancholic subset and controls) and returned higher IL-6 levels than controls. Both depressive groups generated higher PCC scores than controls, with no difference between melancholic and nonmelancholic subsets.ConclusionA sign-based measure to rate melancholia was able to replicate and extend biological findings discriminating melancholic depression. Signs of psychomotor disturbance may be a useful diagnostic measure of melancholia.

show abstract

“…Whether local oestradiol produced by granulosa cells within the ovary also alters extraneuronal neurotrophin expression remains to be determined. However, it has been shown that circulating levels of oestradiol are positively associated with BDNF concentrations in women undergoing fertility treatment (Monteleone et al 2007), and plasma BDNF levels fluctuate during a menstrual cycle (Cubeddu et al 2011), declining in post-menopausal women (Lommatzsch et al 2005, Pluchino et al 2009), but can be increased through hormone replacement . Steroid hormones also influence NGF.…”

Section: R49mentioning

confidence: 99%

The roles of glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor and nerve growth factor during the final stage of folliculogenesis: a focus on oocyte maturation

Linher‐Melville¹,

Li²

2013

Reproduction

View full text Add to dashboard Cite

Neurotrophic factors were first identified to promote the growth, survival or differentiation of neurons and have also been associated with the early stages of ovarian folliculogenesis. More recently, their effects on the final stage of follicular development, including oocyte maturation and early embryonic development, have been reported. Glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are expressed in numerous peripheral tissues outside of the CNS, most notably the ovary, are now known to stimulate oocyte maturation in various species, also enhancing developmental competence. The mechanisms that underlie their actions in antral follicles, as well as the targets ultimately controlled by these factors, are beginning to emerge. GDNF, BDNF and NGF, alone or in combination, could be added to the media currently utilized for in vitro oocyte maturation, thereby potentially increasing the production and/or quality of early embryos.Reproduction (2013) 145 R43-R54

show abstract

Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome

Cited by 79 publications

References 60 publications

Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder

Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder

Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure

The roles of glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor and nerve growth factor during the final stage of folliculogenesis: a focus on oocyte maturation

Contact Info

Product

Resources

About